This piglet model involves surgical instrumentation, asphyxiation until the cardiac arrest, resuscitation, and post-resuscitation observation. The model allows for multiple sampling per animal, and by using continuous invasive arterial blood pressure, ECG, and non-invasive cardiac output monitoring, it provides knowledge about hemodynamics and cardiac pathophysiology in perinatal asphyxia and neonatal cardiopulmonary resuscitation.
Neonatal piglets have been extensively used as translational models for perinatal asphyxia. In 2007, we adapted a well-established piglet asphyxia model by introducing cardiac arrest. This enabled us to study the impact of severe asphyxia on key outcomes, including the time taken for the return of spontaneous circulation (ROSC), as well as the effect of chest compressions according to alternative protocols for cardiopulmonary resuscitation. Due to the anatomical and physiological similarities between piglets and human neonates, piglets serve as good models in studies of cardiopulmonary resuscitation and hemodynamic monitoring. In fact, this cardiac arrest model has provided evidence for guideline development through research on resuscitation protocols, pathophysiology, biomarkers, and novel methods for hemodynamic monitoring. Notably, the incidental finding that a substantial fraction of piglets have pulseless electrical activity (PEA) during cardiac arrest may increase the applicability of the model (i.e., it may be used to study pathophysiology extending beyond the perinatal period). However, the model generation is technically challenging and requires various skill sets, dedicated personnel, and a fine balance of the measures, including the surgical protocols and the use of sedatives/analgesics, to ensure a reasonable rate of survival. In this paper, the protocol is described in detail, as well as experiences with adaptations to the protocol over the years.
Perinatal asphyxia is caused by compromised gas exchange (hypoxemia and hypercapnia) before, during, and/or after birth. It results in reduced blood flow (ischemia) to vital organs and subsequent mixed respiratory and metabolic acidosis. Perinatal asphyxia is a common birth complication that annually causes 580,000 infant deaths worldwide1. Decreasing this number is essential to reduce deaths in newborns and children under 5 years of age, as stated in the United Nations' Sustainable Development Goal number 3.2 (i.e., neonatal mortality <12 per 1,000 live births and under-5 mortality <25 per 1,000 live births)2.
Clinically, asphyxia presents as hypoxic-ischemic encephalopathy (HIE), respiratory depression, and circulatory failure in the newborn infant3 (i.e., symptoms and signs of vital organ hypoxia-ischemia)4. Consequently, an asphyxiated infant may need treatment for encephalopathy, including seizures, and advanced respiratory and circulatory support. Globally, each year, as many as 10 million infants require some form of intervention, such as tactile stimulation, and 6-7 million infants require assisted ventilation at birth5. Thus, perinatal asphyxia puts a huge strain on the health care system, with associated socioeconomic implications. To reduce the global disease burden attributed to perinatal asphyxia, our research groups believe that the following focus areas should be investigated in scientific studies: prevention, including improving prenatal and obstetric care and follow-up; prognostic biomarkers; and optimized delivery room resuscitation and stabilization6.
Newborn piglets and human infants at near-term gestation have similar anatomy and pathophysiology7. Although no animal model of perinatal asphyxia and cardiac arrest can create the full aspect of failed perinatal transition leading to asphyxia and cardiac arrest, piglets are good translational models.
As early as the 1970s, we developed a hypoxia model in adult pigs8. It was successfully refined by research groups9, thus providing a piglet model of perinatal asphyxia10,11,12,13,14,15,16,17,18. In 2007, the first experiments with cardiac arrest in piglets were performed at the Institute for Surgical Research at Oslo University Hospital11,13,15,16. The arrest model has provided evidence for guideline development10,13,15,16,19,20, as well as vast opportunities for physiological studies and the testing of equipment/diagnostic tools14,21, resuscitation protocols (randomized controlled studies)13,15,16,22, and blood and tissue biomarkers10,12,20. Thus, the model has proven to be versatile, and one single experimental series has traditionally been used to answer several research questions. This is important and in agreement with the three Rs (reduction, replacement, and refinement) of experimental animal research23 (i.e., the principle of reducing the number of animals being sacrificed for scientific purposes).
In the following protocol, the piglet model of perinatal asphyxia is described in detail, including how to induce, define, and ascertain cardiac arrest. The model has been refined to minimize exposure to sedatives and surgical interventions and includes mechanical ventilation, asphyxiation, resuscitation, post-resuscitation observation, and the collection of specimens of blood, urine, and cerebrospinal fluid. Our groups also traditionally collect tissues from vital organs postmortem, but the procedure of tissue collection is not described in detail in this protocol. The model simulates a hypoxic insult with mixed respiratory and metabolic acidosis, which reflects the biochemistry of asphyxiated human newborns. By the close monitoring of the piglets with invasive blood pressure (BP) and heart rate (HR), pulse oximetry (PO), electrocardiogram (ECG), impedance cardiography (ICG), and near-infrared spectroscopy (NIRS) assessments, the physiology of perinatal asphyxia, with a particular focus on the heart, can be studied in detail.
The model is technically challenging, as a very fine balance in the medications, surgical interventions, and the method for inducing cardiac arrest is required to ensure a reasonable rate of survival. Conducting the experiments requires thorough preparation and a dedicated and well-functioning team. The selection of experimental animals also seems to play an important role in ensuring successful experiments. In this paper, we describe the protocol in detail and our experiences with it.
The protocol was approved by The Norwegian Food Safety Authority (approval nr. 25030), and the experiments were conducted according to European, Norwegian, and Institutional regulations. The replication of this model requires obtaining ethical approval for the animal experiments in line with institutional and national regulations and ensuring to conduct the experiments according to the three Rs23. All personnel handling the animals need to be certified with functions A, B, and D in accordance with Article 23 and Article 24 of the EU Directive 2010/63/EU24, or equivalent. Carefully monitor the animals during the whole experiment, and adjust the anesthesia, ventilator settings, temperature, and animal positioning to ensure the animals' well-being. Critically assess the model and its application regularly, and refine as required and possible.
NOTE: The piglets used in this study were aged 12-36 h, weighed 1.7-2.3 kg, had equal gender distribution, were of mixed Norwegian Landrace, Duroc, and Yorkshire race, and were genetically unmodified. Step 1 and step 2 of the protocol include general anesthesia and data sampling procedures that apply throughout the experiment, and steps 3-10 detail the experimental procedures, including the preparation of the animals, surgical intervention, asphyxiation until cardiac arrest, resuscitation, and post-resuscitation observation.
1. Anesthesia protocol (TIME: applies to the whole experiment)
2. Data sampling and registrations (TIME: applies to the whole experiment)
3. Preparation (TIME: weeks to months, as long as needed)
4. Reception of piglets (TIME: from 10 min to 2 h, depending on the number of piglets)
5. Induction of anesthesia, intubation, and mechanical ventilation (TIME: 15 min)
6. Surgical intervention (TIME: 20 min)
7. Stabilization (TIME: Minimum 1 h, but as long as needed to stabilize the piglet following surgery and for staff to prepare for the induction of asphyxia)
8. Induction of asphyxia and cardiac arrest (TIME: 15-60 min, varies between piglets)
NOTE: All personnel involved need to know their roles before the induction of asphyxia.
9. Cardiopulmonary resuscitation (CPR) (TIME: 0-15 min)
NOTE: CPR can be conducted according to International Liaison Committee on Resuscitation (ILCOR) guidelines28, with a 3:1 chest compression to ventilation ratio or different ratios of chest compressions to ventilations depending on the aim of the study.
10. Post-ROSC observation (TIME: 9.5 h)
11. Euthanasia (TIME: 10 min)
Figure 1: Sterile table with surgical tools. The surgical tools are prepared and stored on a sterile table before the start of the neck surgery. Please click here to view a larger version of this figure.
Figure 2: Internal jugular vein. The internal jugular vein after it has been dissected free and exposed. Please click here to view a larger version of this figure.
Figure 3: Insertion of the central venous catheter. The suture threads are held just prior to the insertion of the central venous catheter. Please click here to view a larger version of this figure.
Figure 4: Sutures to secure the central venous catheter. The sutures are tied around the vein (and the catheter) to secure the catheter inside the vein. Please click here to view a larger version of this figure.
After the piglets have been instrumented and stabilized, ECG and BP measurements are continuously collected using a data acquisition and analysis software. The hemodynamic changes during asphyxia can easily be seen in the software (Figure 5). The BP drops gradually during asphyxia until cardiac arrest when the BP = 0. After ROSC is achieved, the BP increases, and then after some time, it normalizes again. The BP and ECG data can be used for different types of analyses, for example, the calculation of coronary perfusion pressure during CPR and changes in BP and ECG rhythm and morphology before, during, and/or after asphyxia.
Cardiac stroke volume and cardiac index are continuously monitored with impedance cardiography (a non-invasive cardiac output measurement)21. To study cardiac injury, myocardial markers of oxidative stress and anaerobic metabolism are measured19. In addition, cardiac enzymes including cardiac troponin T can be measured in the plasma (results not yet published).
The asphyxia changes the piglet's physiology. Figure 6 shows an example of how HR (Figure 6A), MAP (Figure 6B), pH (Figure 6C), pCO2 (Figure 6D), base excess (Figure 6E), and lactate (Figure 6F) change throughout the experiment. As expected, MAP, pH, and base excess decrease during asphyxia, while pCO2 and lactate increase (mixed respiratory and metabolic acidosis). Toward the end of the experiment, the values normalize.
Historically, experiments were performed with tracheostomized piglets11,13,15,16,19 (i.e., with a leak-free airway). To limit surgical stress, the piglets were endotracheally intubated with uncuffed ETTs in experiments from 2019. In those experiments21, notably lower ROSC rates were observed. Thus, in recent experiments, we compared ROSC rates using uncuffed versus cuffed ETTs. When using uncuffed ETTs, 7/19 piglets achieved ROSC, and when using cuffed ETTs, 5/5 piglets achieved ROSC (p = 0.012) (unpublished results). This finding supports the importance of a leak-free airway in this model.
Figure 5: Continuous data sampling using the data acquisition and analysis software. An example of how continuous data sampling looks in the data acquisition and analysis software. (A) BP for the whole experiment. (B) Beat-to-beat complexes of BP and ECG. Different parts of the experiment are marked in panel (A): 1) start of asphyxia, 2) cardiac arrest and CPR, 3) ROSC. Please click here to view a larger version of this figure.
Figure 6: Changes in cardiovascular and metabolic variables throughout the experiment. A demonstration of how different variables change throughout the experiment. The six time points that are shown are as follows: just before the start of hypoxia (baseline), 10 min of hypoxia, cardiac arrest, ROSC, 120 min post ROSC, and the end of study (570 min post ROSC). (A) Heart rate (HR), (B) mean arterial pressure (MAP), (C) pH, (D) partial pressure of CO2 (pCO2), (E) base excess, and (F) lactate. Please click here to view a larger version of this figure.
This piglet model is time-consuming and technically challenging, with several critical steps. A fine balance in the medications, surgical interventions, and the method for inducing cardiac arrest is required to ensure a reasonable rate of survival. As the protocol is of a relatively long duration and includes several critical steps, conducting the experiments requires thorough preparation and a dedicated and well-functioning team, and the experiments should be conducted in facilities that have experience with large animal research. Our research teams have performed experiments on one to three piglets in parallel. It is recommended to have at least two people present at all times during the experiments and at least three people if the experiments are to be conducted with three piglets at the same time.
Particularly critical and technically challenging parts of the experiments include the following: 1) making sure all equipment is working and all the data sampling tools are available, working, and calibrated; 2) good and satisfactory mechanical ventilation, particularly before asphyxia and during CPR; 3) surgical intervention; 4) the induction of asphyxia; 5) ascertaining cardiac arrest; 6) CPR; and 7) the sampling of specimens, especially at time-critical points like cardiac arrest and ROSC. The most critical steps in the protocol are the induction of asphyxia and ascertaining cardiac arrest. In the first experiments, CO2 was added to the asphyxia gas to closely mimic the mixed respiratory and metabolic acidosis of perinatal asphyxia10,11,13,14,15,16,20. However, in later experiments7,21,22 where CO2 gas was unavailable, the reduction of the mechanical ventilation rate followed by the clamping of the ETT after 20-30 min was also observed to result in mixed respiratory and metabolic acidosis. High CO2 levels at cardiac arrest are not only important for mimicking the clinical situation but may also influence ROSC. The reason for this might be that cardiac arrest seems to occur at a specific pH, and the pH is dependent on both lactate and CO2. Since hypercapnia is more easily reversed than lactic acidosis, predominantly respiratory versus metabolic acidosis may determine how quickly the piglets recover from the asphyxia. Other piglet models of perinatal asphyxia or HIE often start the reoxygenation/resuscitation before cardiac arrest, typically according to MAP values or the duration of the asphyxia (e.g., 45 min of asphyxia29, 2h of asphyxia30, MAP of 20 mmHg31, MAP of 30-35 mmHg30, MAP 70% below baseline29,32). The advantage of this model is that by inducing cardiac arrest, it is possible to study neonatal CPR and sample data before, during, and right after cardiac arrest. Notably, the incidental finding that a substantial fraction of piglets have PEA7,33 during cardiac arrest may increase the applicability of the model beyond the perinatology field34.
Over the years, the model has been refined to minimize piglet exposure to sedatives and surgical intervention and improve the data sampling and registrations. Prior protocols10,11,13,14,15,16,20 included the induction of anesthesia with sevoflurane. This has now been abandoned, as the current protocol involves directly establishing IV access through an ear vein and IV medications. This is possible as piglet distress is avoided simply by swaddling the piglet in a towel before the peripheral intravenous catheter insertion by a trained provider. Midazolam was also used in the first experimental protocols; however, the subjective assessment of the researcher (R.S.) that performed the vast majority of autopsies was that the brain was in a worse condition during the autopsy if midazolam was used as a continuous infusion. Therefore, we now only use fentanyl IV to maintain anesthesia. Midazolam may be used in bolus doses if the piglet shows signs of distress and fentanyl and/or pentobarbital show no effect; however, we have almost never had to administer it.
In terms of other refinements, in previous experiments, the piglets were tracheostomized with a tightly secured endotracheal tube placed through a subglottic incision. This procedure provides a leak-free airway but causes surgical stress for the piglet. On the other hand, due to the piglet's larger upper airways, endotracheal intubation is associated with significant leakage when using uncuffed ETTs. Therefore, we have started using cuffed ETTs, which has resulted in zero leakage and significantly higher ROSC rates, comparable to experiments with tracheostomized piglets. Furthermore, some adjustments have been made with regard to data sampling. Some of the previous experiments7,19,22,33,35,36 involved the use of a flow probe placed around the left common carotid artery. This flow probe has not been readily available at our institute in Oslo in the last years. Our lab in Edmonton still uses a carotid flow probe, and its use might provide valuable additional hemodynamic data to the model. A few previous experiments also involved the use of a pressure-volume catheter placed in the left ventricle by advancing it through one of the carotids. The administration of chest compressions confounded the pressure-volume catheter registrations and, in some instances, even caused catheter failure and breakage. Thus, its use was abandoned in the arrest model. Recently, non-invasive CO monitors have been added to the protocol, and we are focusing on optimizing the ECG signals during cardiac arrest and CPR, as they might give valuable information on the ECG morphology and PEA. Finally, the post-ROSC observation time has been extended from 4 h to 9.5 h, because 4 h is too short to be able to detect histopathological changes, cell death, and changes in some biomarkers.
One of the most important limitations of this model, and the use of piglets in general as a translational model, is that unlike delivery room CPR, the postnatal cardio-pulmonary transition has already taken place in the piglets. It is improbable that the piglets have open fetal cardiovascular shunts and high pulmonary pressures, as would be the case in an asphyxiated neonate. Although a study by Fugelseth et al.37, which used a previous version of this piglet asphyxia model (not cardiac arrest), showed that vascular shunts are likely to reopen in the piglets during asphyxia, their responses to ventilation and hemodynamic support may differ. Therefore, physiological measurements may not always be representative of a transitioning human neonate. Some anatomical differences between piglets and neonates are also present, such as the larger upper airways in the piglets, which cause ETT leakage (meaning it is important to use cuffed ETTs) and higher basal temperature.
Despite these limitations, there is a long tradition in the global research community of using piglets as a translational model for perinatal asphyxia. The pig is similar to humans in terms of its anatomy, physiology, histology, biochemistry, and inflammation38, and apart from lower birth weights at term (1.5-2.5 kg), the newborn piglet has quite a similar size to the human neonate. The size and anatomy enable instrumentation, monitoring, imaging, and the collection of biological specimens comparable to the human neonate. This model also allows for resuscitation studies as chest compressions are relatively easy to perform in the same manner as in human newborns, and pigs have cardiac anatomy and physiology resembling that of humans39, including the coronary blood distribution, the blood supply to the conduction system, the histologic appearance of the myocardium, and the biochemical and metabolic responses to ischemic injury40. Another important factor is that the newborn piglet has comparable perinatal brain development to the human neonate41, and asphyxia results in a biochemical response with hypercapnia and mixed respiratory and metabolic acidosis, which resembles that of the asphyxiated neonate.
To conclude, this model of perinatal asphyxia is technically challenging and time-consuming. However, it provides valuable information about the physiological and hemodynamical changes during perinatal asphyxia, allows for neonatal resuscitation studies, and provides valuable information on the physiological changes before, during, and after cardiac arrest, which might also be of interest to other research areas in medicine aside from perinatology.
The authors have nothing to disclose.
We would like to thank all the research fellows and researchers that have helped establish, develop, and refine this piglet model of perinatal asphyxia and cardiac arrest in our facilities. We would like to thank the staff at the animal research facilities at the Institute for Surgical Research and Institute for Comparative Medicine, University of Oslo, Norway, and research technicians at the University of Alberta, Edmonton, Canada, for their collaboration during the years. We thank the Medical Student Research Program at the University of Oslo, the Research Council of Norway, and the Norwegian SIDS and Stillbirth Society for the economic support for this publication.
Acid-base machine (ABL 800 Flex) | Radiometer Medical ApS, Brønshøj, Denmark | 989-963 | |
AcqKnowledge 4.0 software for PC | Biopac Systems Inc., Goleta, CA, USA | ACK100W | |
Adhesive aperture drape | OneMed Group Oy, Helsinki, Finland | 1505-01 | |
Adrenaline (1 mg/mL) | Takeda AS, Asker, Norway | Vnr 00 58 50 | Dilute 1:10 in normal saline to 0.1 mg/mL |
Arterial cannula 20 G 1,10 mm x 45 mm | Becton Dickinson Infusion Therapy, Helsingborg, Sweden | 682245 | |
Arterial forceps | Any | ||
Asphyxia gas, 8% oxygen in nitrogen | Linde Gas AS (AGA AS), Oslo, Norway | 110093 | |
Benelyte, 500 mL | Fresenius Kabi, Norge AS, Halden, Norway | 79011 | |
Biopac ECG and invasive blood pressure modules, Model MP 150 | Biopac Systems Inc., Goleta, CA 93117, USA | ECG100C, MP150WSW | |
Box of cardboard for sample storage | Syhehuspartner HF, Oslo, Norway | 2000076 | |
Cannula , 23G x 1 1/4"- Nr.14 | Beckton Dickinson S.A., Fraga, Spain | 300700 | |
Cannula, 18G x 2" | Beckton Dickinson S.A., Fraga, Spain | 301900 | |
Cannula, 21G x 1 1/2"- Nr.2 | Beckton Dickinson S.A., Fraga, Spain | 304432 | |
Centrifuge (Megafuge 1.0R) | Heraeus instruments, Kendro Laboratory Products GmbH, Hanau, Germany | 75003060 | |
Chlorhexidin colored 5 mg/mL | Fresenius Kabi Norge AS, Halden, Norway | 00 73 24 | |
Combi-Stopper | B. Braun Melsungen AG, Melsungen, Germany | 4495101 | |
CRF form | Self-made | ||
Desmarres eyelid retractor 13 cm x 18 mm | Any | ||
Digital Thermometer ama-digit ad 15 th | Amarell, Kreuzwertheim, Germany | 9243101 | |
ECG electrodes, Skintact | Leonhard Lang, Innsbruck, Austria | FS-TC1 /10 | |
Electric heating mattress | Any | ||
Extension set | Codan Medizinische Geräte GmbH & Co KG, Lensahn, Germany | 71.4021 | |
Fentanyl (50 µg/mL) | Hameln, Saksa, Germany | 00 70 16 | |
Fine wood chips | Any | ||
Finnpipette F1, 100-1000 µL | VWR, PA, USA | 613-5550 | |
Fully equipped surgical room | |||
Gas hose | Any | ||
Gauze swabs 5 cm x 5 cm | Bastos Viegas,.a., Penafiel, Portugal | ||
Heparin, heparinnatium 5000 IE/a.e./mL | LEO Pharma AS, Ballerup, Denmark | 46 43 27 | |
HighClean Nonwoven Swabs, 10 cm x 10 cm | Selefa, OneMed Group Ay, Helsinki, Finland | 223003 | |
ICON | Osypka Medical GmbH, Berlin, Germany | Portable non-invasive cardiometer | |
ICON electrodes/ECG electrodes, Ambu WhiteSensor WSP25 | Ambu A/S, Ballerup, Denmark | WsP25-00-S/50 | |
Infusomat Space medical pump | B. Braun Melsungen AG, Melsungen, Germany | 8713050 | |
Invasive blood pressure monitoring system | Codan pvb Critical Care GmbH, Forstinning, Germany | 74.6604 | |
Laryngoscope SunMed Greenlinen blade No 2 | KaWe Medical, Asperg, Germany | ||
Leoni plus mechanical ventilator | Löwenstein Medical SE & Co. KG, Bad Ems, Germany | ||
Liquid nitrogen 230 L | Linde Gas AS (AGA AS), Oslo, Norway | 102730 | |
Microcentrifuge tubes, 1.5 ml | Forsyningssenteret, Trondheim, Norway | 72.690.001 | |
Microcuff endotracheal tube, size 3.5 | Avanos, GA, USA | 35162 | |
Needle holder | Any | ||
Neoflon, peripheral venous catheter, 24 G 0.7 mm x 19 mm | Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden | 391350 | |
Neonatal piglets 12-36 h of age | As young as possible | ||
NIRS electrodes, FORE-SIGHT Single Non-Adhesive Sensor Kit Small | Cas Medical systems Inc., Branford Connecticut, USA | 01-07-2000 | |
NIRS machine, FORE-SIGHT Universal, Cerebral Oximeter MC-202, Benchtop regional oximeter FORE-SIGHT | Cas Medical systems Inc., Branford Connecticut, USA | 01-06-2020 | May also use INVOS, Covidien |
Normal saline, NaCl 9 mg/mL, 500 mL. | Fresenius Kabi Norge AS, Halden, Norway | Vare nr. 141387 | Unmixed |
Normal saline, NaCl 9 mg/mL, 500 mL. | Fresenius Kabi Norge AS, Halden, Norway | 141388 | For IV blood pressure monitoring, add heparin (0.2 ml heparin 5000 IE/a.e./mL in 500 mL of 0.9% NaCl) |
Nunc Cryogenic Tubes 1.8 mL | VWR, PA, USA | 479-6847 | |
Original Perfusor Line, I Standard PE | B. Braun Melsungen AG, Melsungen, Germany | 8723060 | |
Oxygen saturation monitor, MasimoSET, Rad 5 | Masimo, Neuchâtel, Switzerland | 9196 | |
Oxygen saturation monitor, OxiMax N-65 | Covidien LP (formerly Nellcor Puritan Bennett Inc.), Boulder, CO, USA | N65-PDN1 | |
Pentobarbital (100 mg/mL) | Norges Apotekerforening, Oslo, Norway | Pnr 811602 | |
Pipette tips | VWR, PA, USA | 732-2383 | |
Plastic container with holes | Any | Has to allow for circulation of air | |
Printer labels B-492, hvit, 25 mm x 9 mm, 3000 labels | VWR, PA, USA | BRDY805911 | For nunc tubes |
Razor, single use disposable | Any | ||
Rubber gloves | Any | ||
Rubber hot water bottles | Any | ||
Self-inflating silicone pediatric bag 500 ml | Laerdal Medical, Stavanger, Norway | 86005000 | |
Smallbore T-Port Extension Set | B. Braun Melsungen AG, Melsungen, Germany | 471954 | |
Sterile surgical gloves latex, Sempermed supreme | Semperit Technische Produkte Ges.m.b.H., Vienna, Austria | size 7: 822751701 | Different sizes |
Stethoscope | Any | ||
Stopcocks, 3-way, Discofix | B. Braun Melsungen AG, Melsungen, Germany | 16494C | |
Stylet size 3.5 | Any | ||
SunMed Greenlinen laryngoscope blade No 2 | KaWe Medical, Asperg, Germany | ||
Surgical blade, size 15 | Swann Morton LTD, Sheffield England | 205 | |
Surgical forceps | Any | ||
Surgical scissors | Any | ||
Surgical sponges, sterile | Mölnlycke Health Care, Göteborg, Sweden | C0130-3025 | |
Surgical swabs | Mölnlycke Health Care, Göteborg, Sweden | 159860-00 | |
Surgical tape Micropore 2.5 cm x 9.1 m | 3M Norge AS, Lillestrøm, Norway | 153.5 | |
Suture, Monsoft Monofilament Nylon 3-0 | Covidien LP (formerly Nellcor Puritan Bennett Inc.), Boulder, CO, USA | SN653 | |
Suture, Polysorb Braided Absorbable | Covidien LP (formerly Nellcor Puritan Bennett Inc.), Boulder, CO, USA | GL884 | |
Syringe 0.01-1 mL Omnifix F Luer Solo | B. Braun Melsungen AG, Melsungen, Germany | 9161406V | Used for acid base blood sampling. Flush with heparin |
Syringe 10 mL Omnifix Luer Solo | B. Braun Melsungen AG, Melsungen, Germany | 4616103V | |
Syringe 2.5 mL BD Plastipak | Beckton Dickinson S.A., Madrid, Spain | 300185 | Used for blood sampling. Flush with heparinized NaCl |
Syringe 20 mL Omnifix Luer Loc Solo | B. Braun Melsungen AG, Melsungen, Germany | 4617207V | |
Syringe 20 mL Omnifix Luer Solo | B. Braun Melsungen AG, Melsungen, Germany | 4616200V | |
Syringe 5 mL Omnifix Luer Solo | B. Braun Melsungen AG, Melsungen, Germany | 4616057V | |
Syringe 50 mL Omnifix Luer Lock Solo | B. Braun Melsungen AG, Melsungen, Germany | 4617509F | |
Syringe 50 mL Omnifix Luer Solo | B. Braun Melsungen AG, Melsungen, Germany | 4616502F | |
Table drape sheet, asap drytop | Asap Norway AS, Skien, Norway | 83010705 | |
Tape Tensoplast 2.5 cm x 4.5 m | BSN Medical, Essity Medical Solutions, Charlotte, NC, USA | 66005305, 72067-00 | |
Timer | Any | ||
Towels | Any | ||
Transparent IV-fixation | Mediplast AB, Malmö, Sweden | 60902106 | |
Ultrasound gel | Optimu Medical Solutions Ltd. Leeds, UK | 1157 | |
Ultrasound machine, LOGIQ e | GE Healthcare, GE Medical Systems, WI, USA | 5417728-100 | |
Utility drape, sterile | OneMed Group Oy, Helsinki, Finland | 1415-01 | |
Vacuette K3E K3EEDTA 2mL | Greiner Bio-One GmbH, Kremsmünster, Austria | 454222 | |
Venflon Pro Safety 22 G 0.9 mm x 25 mm | Becton Dickinson Infusion Therapy, Helsingborg, Sweden | 393222 | |
Ventilation mask made to fit tightly around a piglet snout | Any | Typically cone shaped | |
Weight | Any |